Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

University of Southern California

Status

Not yet enrolling

Conditions

Lung Non-Small Cell Carcinoma

Treatments

Other: Non-Interventional Study

Study type

Observational

Funder types

Other

Industry

NIH

Identifiers

NCT07339254

2N-25-8 (Other Identifier)

NCI-2025-09218 (Registry Identifier)

P30CA014089 (U.S. NIH Grant/Contract)

HS-25-00563

Details and patient eligibility

About

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Full description

PRIMARY OBJECTIVES:

I. To assess patient satisfaction with receiving IV immune checkpoint inhibitors, reflecting whether the patient thought that the experience was safe, convenient, comfortable and proceeded smoothly.

II. To assess patient preference for IV versus home SC ICI administration.

OUTLINE: This is an observational study.

Patients complete surveys on study.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Age ≥ 18 years.
* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion criteria